Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month

Rhea-AI Summary

Acorda Therapeutics has launched a new television commercial for INBRIJA^® (levodopa inhalation powder) in recognition of Parkinson’s Awareness Month. The ad will be broadcast on around 50 streaming platforms, including Hulu and Paramount+, targeting households identified as affected by Parkinson's disease. The campaign aims to raise awareness about OFF periods in Parkinson's patients and promote INBRIJA as an on-demand treatment option. Additionally, a digital campaign will provide more information and connect viewers with nurse educators. Acorda emphasizes the cost-effectiveness of reaching its audience through streaming services.

Positive

• Launch of a targeted television commercial for INBRIJA during Parkinson’s Awareness Month.
• Commercial to air on 50 streaming services, maximizing outreach.
• Digital campaign to engage viewers and provide educational resources.

Negative

• Risks associated with successfully marketing INBRIJA amidst competition.
• Potential for adverse effects on business operations due to the COVID-19 pandemic.

PEARL RIVER, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched an INBRIJA^® (levodopa inhalation powder) television commercial for Parkinson’s Awareness Month.

The commercial will air on approximately 50 streaming services, including Hulu, the Disney Channel, and Paramount+, and be directed to households who have self-identified as being impacted by Parkinson’s disease. A digital “surround sound” campaign of INBRIJA-branded internet and social media content will coincide with the commercial. Viewers will be able to opt-in to obtain more information or speak directly with a nurse educator.

“Many people with Parkinson’s experience OFF periods, in which their symptoms return in between doses of their regularly scheduled medicines. These can be highly disruptive and over time cause them to narrow their lives. It’s important to educate those living with PD about the need to be proactive in addressing OFF periods, and to consider whether an on-demand medication such as INBRIJA may be helpful to them,” said Kerry Clem, Chief Commercial Officer of Acorda Therapeutics. “In addition, we are able to leverage the power of streaming services to reach those impacted by Parkinson’s significantly more cost-effectively than traditional broadcast tv advertising.”

Interested viewers can see the commercial and learn more about INBRIJA at www.GetInbrija.com.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA^® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS^® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg. For more information about INBRIJA, please visit www.INBRIJA.com.

Forward-Looking Statements

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market AMPYRA, INBRIJA or any other products under development; the COVID-19 pandemic, including related restrictions on in-person interactions and travel, and the potential for illness, quarantines and vaccine mandates affecting our management, employees or consultants or those that work for other companies we rely upon, could have a material adverse effect on our business operations or product sales; our ability to attract and retain key management and other personnel, or maintain access to expert advisors; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures; risks associated with the trading of our common stock; risks related to the successful implementation of our business plan, including the accuracy of its key assumptions; risks related to our corporate restructurings, including our ability to outsource certain operations, realize expected cost savings and maintain the workforce needed for continued operations; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA or AMPYRA to meet market demand; our reliance on third-party manufacturers for the timely production of commercial supplies of INBRIJA and AMPYRA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA or AMPYRA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA outside the U.S.; our ability to satisfy our obligations to distributors and collaboration partners outside the U.S. relating to commercialization and supply of INBRIJA and AMPYRA; competition for INBRIJA and AMPYRA, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of AMPYRA (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions because, among other reasons, acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class-action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third-party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230403005358/en/

Tierney Saccavino

(917) 783-0251

tsaccavino@acorda.com

Source: Acorda Therapeutics

FAQ

What is the new television commercial about launched by ACOR?

Acorda Therapeutics has launched a television commercial for INBRIJA, focusing on raising awareness about Parkinson’s disease and OFF periods.

Where can I watch the new INBRIJA commercial?

The INBRIJA commercial will air on about 50 streaming platforms, including Hulu and Paramount+.

What campaign is Acorda Therapeutics running alongside the INBRIJA commercial?

A digital 'surround sound' campaign will accompany the commercial to provide educational content and facilitate viewer engagement.

How does INBRIJA help Parkinson's patients?

INBRIJA is designed to treat OFF episodes in adults with Parkinson’s disease, providing on-demand medication during symptom returns.

What impact does the COVID-19 pandemic have on Acorda Therapeutics?

The COVID-19 pandemic poses risks to Acorda's business operations, including potential disruptions in marketing and product sales.